Home › Trials › NCT07090161

Iloperidone for adults with uncontrolled high blood pressure

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Phase 2 Interventional Vanda Pharmaceuticals · NCT07090161

We are testing whether iloperidone can lower blood pressure in adults whose blood pressure stays high despite at least 8 weeks of one or more blood pressure medications.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment240 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorVanda Pharmaceuticals Industry-sponsored
Locations28 sites (Phoenix, Arizona and 27 other locations)
Trial IDNCT07090161 on ClinicalTrials.gov

What this trial studies

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 study comparing iloperidone to placebo in adults with uncontrolled hypertension. Eligible participants must have a seated systolic blood pressure ≥130 mmHg despite more than 8 weeks of one or more antihypertensive therapies. Participants with confirmed severe (grade 3) hypertension, unstable cardiac disease, or renal insufficiency are excluded. The trial is sponsored by Vanda Pharmaceuticals and will run at Vanda investigative sites in Phoenix, Tempe, and Tucson, Arizona.

Who should consider this trial

Good fit: Adults with seated systolic BP ≥130 mmHg despite over 8 weeks of one or more antihypertensive drugs, who do not have severe hypertension, unstable heart disease, or significant kidney problems, and who can attend visits at the Arizona sites.

Not a fit: People with confirmed severe (grade 3) hypertension (SiSBP ≥180 mmHg or SiDBP ≥120 mmHg), unstable cardiac disease, renal insufficiency, or those whose blood pressure is already controlled are unlikely to benefit or are excluded.

Why it matters

Potential benefit: If successful, iloperidone could become an additional oral treatment option to help lower blood pressure in people whose hypertension is not controlled by current medications.

How similar studies have performed: Using iloperidone for blood pressure control is a novel approach and there is little prior clinical evidence supporting its use for hypertension.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* SiSBP \>/= 130 mmHg despite \>8 weeks treatment w/ 1 or more antihypertensive therapies

Exclusion Criteria:

* Confirmed Grade 3/severe hypertension (SiSBP \>/= 180 mmHg, SiDBP \>/= 120 mmHg), unstable cardiac disease, renal insufficiency

Where this trial is running

Phoenix, Arizona and 27 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions HypertensionUncontrolled Hypertensioniloperidonehypertensionuncontrolled hypertension
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.